ZEN-3694 + CDK4/6i

About Zenith Epigenetics

Zenith Epigenetics is a clinical-stage biotech based in Calgary, Canada, developing novel BET inhibitors (BETi) for oncology. The company's strategy centers on using its epigenetic platform to develop potent and selective BET inhibitors for use in combination with other targeted agents, aiming to enhance efficacy and combat resistance. Its lead asset, ZEN-3694, is advancing in a Phase 2 randomized trial for prostate cancer and several proof-of-concept studies in rare and aggressive cancers like NUT carcinoma, where it has received FDA Fast Track designation. Zenith operates through collaborations with leading oncology institutions and appears to be structured as a subsidiary or related entity of the public company Zenith Capital Corp.

Therapeutic Areas